AQST · Aquestive Therapeutics, Inc. · Webcasts, Transcripts & Audio
$4.60
+0.03 (+0.67%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$584.88M
Shares
125.51M
Volume · Oct 6
804.2K
Avg daily vol (3M)
2.64M
Aquestive Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Aquestive Therapeutics, Inc. (AQST), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼13.7%
$11.46M
−$12.54M
'22 Q3
22-11-01
▼3.6%
$10.68M
−$12.35M
'22 Q4
23-03-07
▼9.3%
$11.13M
$8.07M
'23 Q1
23-05-02
▼0.2%
$13.24M
−$5.79M
'23 Q2
23-08-07
▲13.4%
$13.00M
−$2.04M
'23 Q3
23-11-06
▲23.6%
$13.21M
−$8.11M
'23 Q4
24-03-05
▲8.3%
$12.05M
−$12.83M
'24 Q1
24-05-07
▲51.8%
$20.10M
−$2.75M
'24 Q2
24-08-06
▲4.2%
$13.54M
−$11.51M
'24 Q3
24-11-04
▼10.1%
$11.87M
−$17.05M
'24 Q4
25-03-05
▼27.7%
$8.72M
−$22.93M
'25 Q1
25-05-12
▼50.2%
$10.00M
−$13.55M
'25 Q2
25-08-11
▼5.4%
$12.81M
−$15.45M
'25 Q3
25-11-05
▲9.7%
$13.02M
−$31.86M
'25 Q4
26-03-05
▲65.7%
$14.45M
−$8.06M
'26 Q1
26-05-14
LATEST
▲38.1%
$13.82M
−$22.86M
'26 Q2
26-08-12
Earnings call
FY26 · Q2
2026-08-12
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call
Revenue
$13.82M
▲ 38.1% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Confident tone
FDA Review and Expedited Pathways
Anifilm NDA Resubmission Timeline
AQST-108 Pipeline and TSLP Biomarker
Revenue
$14.45M
▲ 65.7% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
Confident tone
ANNAFILM NDA resubmission and FDA path
Commercial launch readiness
Capital and financing
Revenue
$13.02M*
▲ 9.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call
Positive tone
Pipeline program AQST-108 / Adrenaverse
Anifilm FDA resubmission and review timing
Commercial launch preparation
Revenue
$12.81M
▼ 5.4% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript
Positive tone
Anaphylm FDA review and approval timeline
Launch financing and capital position
Payer access barriers and patient-first approach
Revenue
$10.00M
▼ 50.2% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript
Confident tone
Anaphylm FDA review and launch preparation
Payer engagement and existing Libervant contracts
Commercial team and marketing buildout
Revenue
$8.72M
▼ 27.7% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-05
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript
Confident tone
Libervant commercial and legal risk
Sales force and commercial launch planning
Awareness trial and usage study (ATU)
Revenue
$11.87M*
▼ 10.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call Transcript
Confident tone
Anaphylm regulatory progress and FDA alignment
Libervant commercial launch and market access
OASIS study results for Anaphylm
Revenue
$13.54M
▲ 4.2% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Aquestive Therapeutics, Inc. (AQST) Q2 2024 Earnings Call Transcript
Confident tone
Anaphylm development and regulatory progress
Libervant launch and expansion
Financial guidance and cash position
Revenue
$20.10M
▲ 51.8% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Call Transcript
Confident tone
Anaphylm clinical progress and filing timeline
Libervant FDA approval and commercial rollout (2 to 5)
Pediatric study and labeling strategy for Anaphylm
Revenue
$12.05M
▲ 8.3% YoY Diluted EPS
$-0.17
▼ 254.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-05
Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript
Revenue
$13.21M*
▲ 23.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Aquestive Therapeutics, Inc. (AQST) Q3 2023 Earnings Call Transcript
Revenue
$13.00M
▲ 13.4% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Call Transcript
Revenue
$13.24M
▼ 0.2% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Aquestive Therapeutics, Inc. (AQST) Q1 2023 Earnings Call Transcript
Revenue
$11.13M
▼ 9.3% YoY Diluted EPS
$0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Aquestive Therapeutics, Inc. (AQST) Q4 2022 Earnings Call Transcript
Revenue
$10.68M*
▼ 3.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Aquestive Therapeutics, Inc. (AQST) Q3 2022 Earnings Call Transcript
Revenue
$11.46M
▼ 13.7% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Aquestive Therapeutics, Inc. (AQST) Q2 2022 Earnings Call Transcript
Revenue
$13.27M
▼ 13.6% YoY Diluted EPS
$-0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Aquestive Therapeutics, Inc. (AQST) Q1 2022 Earnings Call Transcript
Revenue
$12.27M
▲ 10.3% YoY Diluted EPS
$-0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Aquestive Therapeutics, Inc. (AQST) Q4 2021 Earnings Call Transcript
Revenue
$11.08M*
▲ 55% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Call Transcript
Revenue
$13.29M
▲ 60.9% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Aquestive Therapeutics, Inc. (AQST) Q2 2021 Earnings Call Transcript
Revenue
$15.35M
▼ 29.2% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Aquestive Therapeutics, Inc. (AQST) Q1 2021 Earnings Call Transcript
Revenue
$11.12M
▲ 26.9% YoY Diluted EPS
$-0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Aquestive Therapeutics, Inc. (AQST) Q4 2020 Earnings Call Transcript
Revenue
$7.15M
▼ 56.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Aquestive Therapeutics, Inc. (AQST) Q3 2020 Earnings Call Transcript
Revenue
$8.26M
▼ 33.5% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Aquestive Therapeutics, Inc. (AQST) Q2 2020 Earnings Call Transcript
Revenue
$21.68M
▲ 94.8% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Aquestive Therapeutics, Inc. (AQST) Q1 2020 Earnings Call Transcript
Revenue
$8.77M
▼ 30.7% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-11
Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call
Revenue
$16.42M
▼ 2.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 webcasts